Hi Dyeman & All,
Yes normally you would require a larger cohort to establish safety & efficacy, but rare disease status/orphan status is not classed in the “normal” trial design range. These patients are harder to recruit due to rare disease (and we in fact saw this, opening up a new trial site in WA towards the end of recruitment).
(N=10) is perfectly fine for a rare disease trial:
Not all patients reached the high bar of 50% above SOC (Ibersartan), but the average was 36% above SOC. I think it’s also important to note the responders in light blue in the figure above, their diagnosis was undisclosed as “other” in an a trial of n=27, the subgroup analysis is listed below:
https://www.asx.com.au/asxpdf/20171102/pdf/43nx4g3z7l9zgv.pdf
Iga Nephropathy were excluded from the trial inspite of being responders, when it was first planned to include them, Why?
(n=2) did not complete the trial for reasons otherwise. 1 didn’t complete data requirements. So that equates to 23. It’s wise what the company did when (n=40) for DKD for meaningful statistical analysis & in fact recruited (n=45). It could have been a nightmare especially in the current climate of COVID. Same goes for FSGS.
I think it’s also pretty wise to take on board that all on current 2a & 2b Trials for FSGS & DKD were required to be on a stable dose of 300mg of Irbesartan, whereas the prior trial of Ph2A of all-comers for CKD were not, a stable dose of 75mg & above, so 150mg & 300mg. This could make a difference to efficacy, so it’s really good they randomised their current trials in such a way, as the drugs work in synergy.
https://www.asx.com.au/asxpdf/20171102/pdf/43nx5vslh0d9r7.pdf
Good luck all & HAGWE.
- Forums
- ASX - By Stock
- DXB
- Ann: Quarterly Appendix 4C and Activities Report
Ann: Quarterly Appendix 4C and Activities Report, page-210
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
48.0¢ |
Change
0.040(9.09%) |
Mkt cap ! $255.8M |
Open | High | Low | Value | Volume |
44.0¢ | 48.0¢ | 44.0¢ | $1.016M | 2.186M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 61262 | 47.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.5¢ | 190191 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 67842 | 0.460 |
7 | 216964 | 0.455 |
10 | 198203 | 0.450 |
6 | 371444 | 0.445 |
5 | 57618 | 0.440 |
Price($) | Vol. | No. |
---|---|---|
0.465 | 13505 | 1 |
0.470 | 169134 | 7 |
0.475 | 82954 | 7 |
0.480 | 250462 | 6 |
0.485 | 118591 | 4 |
Last trade - 12.02pm 10/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online